Black Diamond Therapeutics Inc logo

BDTX - Black Diamond Therapeutics Inc News Story

$25.5 -0.1  -0.2%

Last Trade - 07/05/21

Sector
Healthcare
Size
Mid Cap
Market Cap £660.0m
Enterprise Value £434.5m
Revenue £n/a
Position in Universe 2925th / 6858

BRIEF-Black Diamond Therapeutics - FDA Notified Co That It May Only Enroll Up To 50 Patients In A Certain Phase 2 Study For Bdtx-189

Mon 15th March, 2021 11:40am
March 15 (Reuters) - Black Diamond Therapeutics Inc
 BDTX.O :
    * BLACK DIAMOND THERAPEUTICS - FDA NOTIFIED CO THAT IT MAY
ONLY
ENROLL UP TO 50 PATIENTS IN A CERTAIN PHASE 2 STUDY FOR BDTX-189
    * BLACK DIAMOND THERAPEUTICS INC - HAS INITIATED GLP
TOXICOLOGY
STUDIES AND DOES NOT ANTICIPATE ANY DELAYS TO ITS CLINICAL TRIAL
TIMELINES FOR BDTX-189

Source text for Eikon: [https://bit.ly/3lhALZe]
Further company coverage:  BDTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.